{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:51:32Z","timestamp":1768463492413,"version":"3.49.0"},"reference-count":29,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2020,7,12]],"date-time":"2020-07-12T00:00:00Z","timestamp":1594512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Donor lymphocyte infusion (DLI) is used to prevent or treat haematological malignancies relapse after allogeneic stem cell transplantation (allo-SCT). Recombinant human granulocyte colony-stimulated factor primed DLI (gDLI) is derived from frozen aliquots of the peripheral blood stem cell collection. We compared the efficacy and safety of gDLI and classical DLI after allo-SCT. We excluded haploidentical allo-SCT. Initial diseases were acute myeloblastic leukaemia (n = 45), myeloma (n = 38), acute lymphoblastic leukaemia (n = 20), non-Hodgkin lymphoma (n = 10), myelodysplasia (n = 8), Hodgkin lymphoma (n = 8), chronic lymphocytic leukaemia (n = 7), chronic myeloid leukaemia (n = 2) and osteomyelofibrosis (n = 1). Indications for DLI were relapse (n = 96) or pre-emptive treatment (n = 43). Sixty-eight patients had classical DLI and 71 had gDLI. The response rate was 38.2%, the 5-year progression-free survival (PFS) rate was 38% (29\u201348) and the 5-year overall survival (OS) rate was 37% (29\u201347). Graft versus host disease rate was 46.7% and 10.1% of patients died from toxicity. There were no differences between classical DLI and gDLI in terms of response (p = 0.28), 5-year PFS (p = 0.90), 5-year OS (p. 0.50), GvHD (p = 0.86), treated GvHD (p = 0.81) and cause of mortality (p. 0.14). In conclusion, this study points out no major effectiveness or toxicity of gDLI compared to classical DLI.<\/jats:p>","DOI":"10.3390\/jcm9072204","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T11:03:23Z","timestamp":1594724603000},"page":"2204","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Retrospective Comparison of DLI and gDLI for Post-Transplant Treatment"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-305X","authenticated-orcid":false,"given":"Sylvain","family":"Lamure","sequence":"first","affiliation":[{"name":"Department of Clinical Haematology, CHU Montpellier, 34295 Montpellier, France"},{"name":"Federation of Haematology, University of Montpellier, 34295 Montpellier, France"},{"name":"UMR-CNRS 5535, Institut de G\u00e9n\u00e9tique Mol\u00e9culaire de Montpellier, 34090 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franciane","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, CHU Montpellier, 34295 Montpellier, France"},{"name":"Federation of Haematology, University of Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Laure","family":"Gagez","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, CHU Montpellier, 34295 Montpellier, France"},{"name":"Direction de la Strat\u00e9gie, des Affaires M\u00e9dicales et de l\u2019Innovation, Sant\u00e9lys Association, 59120 Loos, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00e9my","family":"Delage","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, CHU Montpellier, 34295 Montpellier, France"},{"name":"Clinique du Parc, 34170 Castelnau le Lez, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Vincent","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, CHU Montpellier, 34295 Montpellier, France"},{"name":"Federation of Haematology, University of Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Fegueux","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, CHU Montpellier, 34295 Montpellier, France"},{"name":"Federation of Haematology, University of Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Sirvent","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, CHU Montpellier, 34295 Montpellier, France"},{"name":"Federation of Haematology, University of Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eve","family":"Gehlkopf","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, CHU Montpellier, 34295 Montpellier, France"},{"name":"Federation of Haematology, University of Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Luc","family":"Veyrune","sequence":"additional","affiliation":[{"name":"Department of Cell and Tissue Engineering, University of Montpellier, CHU Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu Zhao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cell and Tissue Engineering, University of Montpellier, CHU Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarik","family":"Kanouni","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, CHU Montpellier, 34295 Montpellier, France"},{"name":"Federation of Haematology, University of Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e8re","family":"Cacheux","sequence":"additional","affiliation":[{"name":"Department of Biological Haematology, CHU Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5717-3207","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Moreaux","sequence":"additional","affiliation":[{"name":"Department of Biological Haematology, CHU Montpellier, 34295 Montpellier, France"},{"name":"IGH, CNRS, University of Montpellier, 34094 Montpellier, France"},{"name":"Institut Universitaire de France, 75005 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Bonafoux","sequence":"additional","affiliation":[{"name":"Department of Immunology, CHU Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, CHU Montpellier, 34295 Montpellier, France"},{"name":"Federation of Haematology, University of Montpellier, 34295 Montpellier, France"},{"name":"UMR-CNRS 5535, Institut de G\u00e9n\u00e9tique Mol\u00e9culaire de Montpellier, 34090 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"De Vos","sequence":"additional","affiliation":[{"name":"Federation of Haematology, University of Montpellier, 34295 Montpellier, France"},{"name":"Department of Cell and Tissue Engineering, University of Montpellier, CHU Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Ceballos","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, CHU Montpellier, 34295 Montpellier, France"},{"name":"Federation of Haematology, University of Montpellier, 34295 Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","article-title":"Graft-versus-leukemia effects of transplantation and donor lymphocytes","volume":"112","author":"Kolb","year":"2008","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.transci.2016.05.011","article-title":"Donor lymphocyte infusion after allogeneic stem cell transplantation","volume":"54","author":"Castagna","year":"2016","journal-title":"Transfus. Apher. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/CCO.0b013e328335a559","article-title":"Biology and clinical effects of natural killer cells in allogeneic transplantation","volume":"22","author":"Benjamin","year":"2010","journal-title":"Curr. Opin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/bmt.2014.2","article-title":"Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: A prospective phase II trial","volume":"49","author":"Solomon","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/bmt.2014.227","article-title":"A multicentre UK study of GVHD following DLI: Rates of GVHD are high but mortality from GVHD is infrequent","volume":"50","author":"Scarisbrick","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.exphem.2012.02.009","article-title":"Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma","volume":"40","author":"Crocchiolo","year":"2012","journal-title":"Exp. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bbmt.2014.12.016","article-title":"Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions\u2014A retrospective multicenter analysis from the German Cooperative Transplant Study Group","volume":"21","author":"Schroeder","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/bmt.2016.129","article-title":"Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation","volume":"51","author":"Tsirigotis","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.clml.2013.09.010","article-title":"A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation","volume":"14","author":"Shanavas","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/bmt.2011.45","article-title":"Induction of graft versus malignancy effect after unrelated allogeneic PBSCT using donor lymphocyte infusions derived from frozen aliquots of the original graft","volume":"47","author":"Hasskarl","year":"2012","journal-title":"Bone Marrow Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s10875-007-9166-z","article-title":"Modified donor lymphocyte infusion after HLA-mismatched\/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia","volume":"28","author":"Huang","year":"2008","journal-title":"J. Clin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s10875-008-9193-4","article-title":"Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia--feasibility and safety study","volume":"28","author":"Huang","year":"2008","journal-title":"J. Clin. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1399-0012.2012.01618.x","article-title":"Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: Incidence and risk factors","volume":"26","author":"Yan","year":"2012","journal-title":"Clin. Transplant."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.4049\/jimmunol.175.11.7085","article-title":"Granulocyte colony-stimulating factor: A novel mediator of T cell tolerance","volume":"175","author":"Rutella","year":"2005","journal-title":"J. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6631","DOI":"10.4049\/jimmunol.176.11.6631","article-title":"Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor","volume":"176","author":"Condomines","year":"2006","journal-title":"J. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host Disease in human recipients of marrow from HL-A-matched sibling donor,S","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/sj.bmt.1701779","article-title":"Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection","volume":"23","author":"Thiede","year":"1999","journal-title":"Bone Marrow Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.patbio.2014.05.011","article-title":"Prophylactic, preemptive and curative use of donor lymphocyte infusion in patients undergoing allogeneic stem cell transplantation: Guidelines of the SFGM-TC","volume":"62","author":"Guillaume","year":"2014","journal-title":"Pathol. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1056\/NEJMp078166","article-title":"Hematopoietic-cell transplantation at 50","volume":"357","author":"Appelbaum","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/leu.2011.351","article-title":"Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT","volume":"26","author":"Spyridonidis","year":"2012","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/sj.bmt.1702596","article-title":"Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: Lower incidence of acute graft-versus-host disease and improved outcome","volume":"26","author":"Shiobara","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bbmt.2007.04.013","article-title":"High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma","volume":"14","author":"Bloor","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1200\/JCO.2010.32.1711","article-title":"Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin\u2019s lymphoma","volume":"29","author":"Peggs","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.bbmt.2012.12.013","article-title":"Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes","volume":"19","author":"Krishnamurthy","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.bmt.1705981","article-title":"A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation","volume":"41","author":"Lutz","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1083-8791(03)00077-6","article-title":"Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation","volume":"9","author":"Dey","year":"2003","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjh.15881","article-title":"G-CSF administration prior to donor lymphocyte apheresis promotes anti-leukaemic effects in allogeneic HCT patients","volume":"186","author":"Schneidawind","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/bmt.2012.144","article-title":"G-CSF mobilized vs conventional donor lymphocytes for therapy of relapse or incomplete engraftment after allogeneic hematopoietic transplantation","volume":"48","author":"Abbi","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.clml.2015.10.004","article-title":"Donor Lymphocyte Infusion in Hematologic Malignancies\u2014Good to be Fresh?","volume":"16","author":"Hossain","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/7\/2204\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:50:35Z","timestamp":1760176235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/7\/2204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,12]]},"references-count":29,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["jcm9072204"],"URL":"https:\/\/doi.org\/10.3390\/jcm9072204","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,12]]}}}